Navigation Links
Covance and the Indiana CTSI to collaborate on early clinical research
Date:9/4/2013

PRINCETON, N.J., and INDIANAPOLIS -- Covance Inc. (NYSE: CVD), a leading global drug development services company, and the Indiana Clinical and Translational Sciences Institute, part of the Indiana University School of Medicine, today announced an agreement to collaborate in conducting early clinical trials for new medicines on behalf of biotechnology and pharmaceutical companies.

This alliance provides a significant opportunity to bring more Phase I clinical research to Indiana, through the clinical research unit located within the IU School of Medicine in Indianapolis and Covance's clinical research unit located in Evansville. Phase I clinical research includes studies where investigational new drugs are administered to humans for the first time.

Working together, the two organizations will conduct high-quality research in a safe and regulated environment for sponsors who are looking to recruit both healthy volunteers and patients for early clinical studies.

"The alliance with the Indiana CTSI will help us provide biopharmaceutical clients with quicker access to patients in a hospital setting that supports specialized care and monitoring," said Rob Aspbury, vice president and general manager, Global Clinical Pharmacology Services at Covance. "With quicker access to patients, we can streamline the drug development process and bring important new medications to patients who need them."

The Indiana CTSI will provide access to a 13,606-square-foot, 24-patient facility at IU Health University Hospital in Indianapolis. The institute also stands ready to expand operations into a recently renovated 33,078-square-foot, 50-patient facility in the same building. This space re-opens to clinical research for the first time in six years due to the efforts of the Indiana CTSI.

"The Indiana CTSI works every day to support tremendously talented biomedical scientists whose discoveries have the potential to translate into life-saving new therapies and treatments," said Anantha Shekhar, M.D., Ph.D., director of the Indiana CTSI, associate dean for translational research, and the Raymond E. Houk Professor of Psychiatry at the IU School of Medicine. "Our mission is to accelerate the rate at which this research travels out of the lab and into the care of the patients who need it. This alliance with Covance will greatly enhance our ability to accomplish this vital work."

Services provided by the Indiana CTSI include access to 24-hour nursing support, in-patient and out-patient facilities, on-site laboratory analyses and professional patient recruitment services. These patient recruitment efforts are strengthened through robust patient data from the Regenstrief Institute, a partner of the Indiana CTSI which houses the Indiana Network for Patient Care, in which more than 70 Indiana hospitals share nearly 80 percent of the state's electronic medical record data. Additional patient and support services are provided through its affiliation with IU Health.

The alliance between Covance and the Indiana CTSI was facilitated by BioCrossroads, an organization that advances Indiana's signature strengths in the life sciences by connecting corporations, academic institutions and philanthropic organizations.

"This is a major milestone for both Covance and the Indiana CTSI. It's the type of public-private partnership that really can influence breakthroughs in medicine," said Deborah Keller, executive vice president and group president, R&D Laboratories at Covance, and a member of the BioCrossroads Board of Directors. "Indiana is unique in its depth and breadth of drug development opportunities, both on the corporate and academic sides, and this collaboration is a shining example of bringing the two together thanks to the work and support of BioCrossroads."

Covance has been conducting Phase I clinical trials for more than 35 years. In addition to its 80-bed clinical research unit in Evansville, Ind., Covance has clinics in Madison, Wis.; Daytona, Beach, Fla.; Dallas, Texas; and Leeds, UK. In 2012, Covance conducted more than 100 Phase I trials globally. Covance also has a similar Phase I clinical research alliance with the Royal Liverpool University Hospital in Liverpool, UK.


'/>"/>

Contact: Kevin Fryling
kfryling@iu.edu
317-278-0088
Indiana University
Source:Eurekalert

Related medicine news :

1. Indiana’s Largest Optical Retailer Forges Exclusive Partnership with Rising Philanthropic Eyewear Brand
2. Viewpoints Industry TV Welcomes Evansville, Indiana to Its Viewing Area
3. New Report: Statewide Smokefree Law Would Not Hurt Indiana Restaurant, Bar Businesses
4. New Incline Platform Wheelchair Lift from Butler Mobility is Carried by Access Elevator Serving Southern Wisconsin, Northern Illinois and Northwest Indiana
5. Indianapolis Colts Renew 20/20 Institute as Official LASIK Provider
6. Blake Shelton Tickets: Cheap Concert Tickets Slashes Ticket Prices in Long Island, Virginia Beach, Indianapolis, DC, St. Louis, Cincinnati, Pittsburgh, Chicago & Camden
7. Superior Van & Mobility Announces Participation in the "My Finish Line" Movie and Music Tour at their Evansville, Indiana location July 30th from 2 to 5 p.m.
8. Elevate Ventures Partners with Southwest Indiana Region Community Stakeholders to Launch Regional Entrepreneurship Action Plan
9. Certified ScrumMaster Training Weekend Edition August 24-25 in Indianapolis Presented by BeardedEagle
10. The Eagles Tickets in Lincoln, Denver, Tulsa, Wichita, Dallas, Memphis, Nashville, Indianapolis, Chicago Rosemont, Moline, Kansas City & St. Louis Presales Begin 6/7/13
11. Seva Call Launches in Flood Hit Fort Wayne, Indiana
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Cosmetic Town, an online plastic ... cosmetic surgeries they perform on a daily basis. , The new video series ... they specialize in at their practices. , When asked about the new video ...
(Date:7/24/2017)... ... July 24, 2017 , ... ... California effectively destroyed the construction site and threatened numerous homes and businesses nearby, ... article on NBCLosAngeles.com. Los Angeles Area consulting firm Fire Protection Group, ...
(Date:7/24/2017)... (PRWEB) , ... July 24, 2017 , ... Every year, ... invigorating and educational conference, InstructureCon. Each annual event is coupled with a dynamic theme ... with a James Bond theme, Mission: InstructureCon 0017. , To extend their partnership ...
(Date:7/24/2017)... PHILADELPHIA (PRWEB) , ... July 24, 2017 , ... ... Health , two organizations that already work hand-in-hand on an Innovation Collaboration program, ... transform the access, quality, experience and cost of the care members and patients ...
(Date:7/24/2017)... , ... July 24, 2017 , ... Anyone who uses ... a watermelon, nor would a pharmacist using that same scale to dispense medication. The ... health. , These illustrations show why it is important to have the right ...
Breaking Medicine News(10 mins):
(Date:7/14/2017)... Endo International plc (NASDAQ: ENDP ) will announce its ... its senior management team will host a conference call and webcast ... The dial-in number to access the call is U.S./ ... passcode is 45397076. Please dial in 10 minutes prior to the ... replay of the call will be available from August 8, 2017 ...
(Date:7/13/2017)...  New York City-based market research firm Kalorama Information notes ... of.  From new products to new costs, to the threat ... completed study, Potential Pipeline Disruptors . Among ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... impact the growing population and, to a more extreme extent, ...
(Date:7/11/2017)... N.J. , July 11, 2017  Bayer has awarded ... eight countries as part of its prestigious Bayer Hemophilia Awards ... Hospital of Philadelphia and Uniformed Services ... are among the winners. Grant recipients were announced last ... and Hemostasis (ISTH) 2017 Congress, Berlin, Germany ...
Breaking Medicine Technology: